Mika Scheinin

University of Turku, Turku University Hospital

Papers

Total Citations

H-Index

About

Mika Scheinin is a prominent pharmacologist whose research centers on adrenergic receptor pharmacology, particularly the alpha2-adrenoceptor system, and the development of advanced methodologies for preclinical drug screening. His major contributions include pioneering high-throughput screening techniques for identifying novel modulators of human alpha2-adrenoceptors, as demonstrated in his 2012 study that introduced a miniaturized radioligand competition assay. This work has been cited 8 times and represents a significant methodological advance for drug discovery. Scheinin has also made important contributions to behavioral pharmacology, notably through his 2014 comparative study of radiotelemetry and photobeam methods for measuring mouse locomotor activity (4 citations), which improved the accuracy of preclinical behavioral assessments. His research bridges fundamental receptor biology with translational applications, providing tools that enhance the efficiency and reliability of early-stage drug development. Scheinin’s work is particularly valued for its technical rigor and practical impact on how researchers evaluate drug-receptor interactions and behavioral outcomes in animal models, making him a respected figure in neuropharmacology and experimental pharmacology.